The stock of Coherus Biosciences Inc (NASDAQ:CHRS) is a huge mover today! About 97,838 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 35.67% since March 7, 2016 and is uptrending. It has outperformed by 28.08% the S&P500.
The move comes after 6 months positive chart setup for the $1.32 billion company. It was reported on Oct, 10 by Barchart.com. We have $35.34 PT which if reached, will make NASDAQ:CHRS worth $316.80 million more.
Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on November, 14. They expect $-1.71 earnings per share, up 8.06% or $0.15 from last year’s $-1.86 per share. After $-1.72 actual earnings per share reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -0.58% EPS growth.
Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage
Out of 5 analysts covering Coherus Biosciences (NASDAQ:CHRS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Coherus Biosciences has been the topic of 5 analyst reports since September 3, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock to “Hold” rating in Thursday, September 3 report. The rating was initiated by Barclays Capital with “Overweight” on Monday, November 23. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) earned “Buy” rating by Citigroup on Wednesday, July 27. Credit Suisse initiated Coherus Biosciences Inc (NASDAQ:CHRS) on Wednesday, January 20 with “Outperform” rating. Maxim Group initiated the stock with “Buy” rating in Wednesday, September 7 report.
According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”
Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.99, from 1.33 in 2016Q1. The ratio increased, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.
Fmr Lc has 6.40 million shares for 0.01% of their US portfolio. The Illinois-based Northern Tru Corporation has invested 0% in Coherus Biosciences Inc (NASDAQ:CHRS). Highland Cap Management Limited Partnership accumulated 327,044 shares or 0.23% of the stock. Legal General Gp Public Limited Com last reported 4,114 shares in the company. Royal National Bank Of Canada reported 600 shares or 0% of all its holdings. The France-based Axa has invested 0.03% in Coherus Biosciences Inc (NASDAQ:CHRS). Columbus Circle Investors last reported 0.06% of its portfolio in the stock. Allianz Asset Ag, a Germany-based fund reported 46,259 shares. Wfg Advisors Ltd Partnership last reported 0.01% of its portfolio in the stock. Cormorant Asset Management Limited Liability Co reported 576,106 shares or 1.38% of all its holdings. The Germany-based Commerzbank Aktiengesellschaft Fi has invested 0% in Coherus Biosciences Inc (NASDAQ:CHRS). Citadel Advsrs Limited Liability Co last reported 675,732 shares in the company. Kohlberg Kravis Roberts And Company Lp holds 0.54% or 3.06 million shares in its portfolio. Tiaa Cref Investment Ltd Llc holds 0.01% or 725,122 shares in its portfolio. Dekabank Deutsche Girozentrale accumulated 0% or 22,400 shares.
More notable recent Coherus Biosciences Inc (NASDAQ:CHRS) news were published by: Globenewswire.com which released: “Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License …” on October 06, 2016, also Fool.com with their article: “Why Coherus BioSciences Inc. Shares Burst Today” published on April 01, 2015, Fool.com published: “Coherus Biosciences and Baxalta Take Aim at Amgen and Pfizer” on January 12, 2016. More interesting news about Coherus Biosciences Inc (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results” published on August 09, 2016 as well as Streetinsider.com‘s news article titled: “Coherus BioSciences (CHRS) CHS-1701 Follow-on Study Met All co-Primary Endpoints” with publication date: July 11, 2016.
CHRS Company Profile
Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.